CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
以维奈克拉为基础的联合治疗用于 CAR-T 治疗失败的 R/R DLBCL 患者
英文原题：Venetoclax-based combination therapy in R/R DLBCL patients with failure of CAR-T therapy.
查看英文原题
Venetoclax-based combination therapy in R/R DLBCL patients with failure of CAR-T therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 治疗失败后的复发/难治性DLBCL患者可选的有效治疗很少。本研究回顾性评估了本中心2020年7月至2021年12月间接受CAR-T 治疗后失败并接受维奈克拉联合方案治疗的10名复发/难治性DLBCL患者；这些患者均有完整临床记录。CAR-T 治疗后，所有患者均在数月内复发，之后均接受维奈克拉联合方案作为挽救治疗。客观缓解率（ORR）为80%，完全缓解率为30%。分析时有7名患者仍存活。本研究显示，对于CAR-T 治疗失败的复发/难治性DLBCL患者，维奈克拉联合治疗有效率较高，毒性可管理。
展开英文摘要原文
There are few effective therapeutic options available for R/R DLBCL patients who have undergone CAR-T therapy.
We retrospectively assessed 10 R/R DLBCL patients with complete clinical records who received venetoclax-based combination therapy following CAR-T therapy failed in our center between July 2020 and December 2021. After receiving CAR-T therapy, they all relapsed within a few months. As salvage regimens, they were all given venetoclax-based combination therapy. The objective response rate (ORR) was 80 percent, and the complete response rate was 30 percent. At the time of the analysis, 7 patients were still living.
Our research has demonstrated that venetoclax-based combination treatment for R/R DLBCL patients who failed CAR-T therapy has a high effectiveness and manageable toxicity.
论文信息
- 作者
- Zhu Y、Ai S、Cong M、Jin M、Ma X、Huang H
- 第一作者单位
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.China
- 通讯作者单位
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. huanghaiwen@suda.edu.cn.China
- 期刊
- Annals of hematology2023 Mar
- 原文标识
- PubMed 36710282 · DOI 10.1007/s00277-023-05088-7